Utah Medical Products, Inc. (UTMD) Guidance & Earnings Results
On 2026-07-23 Utah Medical Products, Inc. lowered guidance: "Revenue decline of 14.3% in Q2 2026 vs Q2…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
UTMDUtah Medical Products, Inc.Follow UTMD — free
—
Price chart with a free account
- Market cap
- 236.3M
- P/E TTM
- 22.6
- Dividend yield
- 1.7%
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 23 Jul 26 | Lowered | Revenue decline of 14.3% in Q2 2026 vs Q2 2025 |
| 24 Jul 25 | Reaffirmed | FY2025 PendoTECH sales expected ~$2M lower than FY2024; 2H 2025 PendoTECH sales ~$200 lower than 2H 2024 · full year |
Utah Medical Products, Inc. — questions
- What guidance did Utah Medical Products, Inc. give?
- On 2026-07-23: "Revenue decline of 14.3% in Q2 2026 vs Q2 2025"
- When does Utah Medical Products, Inc. report earnings?
- Utah Medical Products, Inc.'s next earnings report is expected on 2026-10-27.
Every figure on this page comes from Utah Medical Products, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.